Xavier Liogier d’Ardhuy, PhD, is the Chief of Translational Science of the Loulou Foundation, leading the critical efforts to establish and validate clinical outcome measures and biomarkers for CDKL5 deficiency disorder. Xavier is Neuropsychologist by training with 20 years of experience in CNS drug development, specialized in Neurodevelopment Disorders (NDD).
After several years in the Roche Clinical Pharmacology department, Xavier joined the Roche Neuroscience early development team as Clinical Scientist, focusing on NDD projects such as Down syndrome and Autism. In this context, he designed and led observational studies as well as phase 2 trials. He was a Roche representative in European Autism consortia (EU-AIMS and InFoR) to bring industry expertise in clinical trial settings. As a Neuropsychologist with industry experience, Xavier was also a member of NICHD working groups at the US NIH to evaluate and advise on clinical endpoints for Down syndrome clinical trials, and to develop strategies for drug development in intellectual disability. He then joined STALICLA, a Swiss biotech, as Chief of Translational Development, to support the clinical development of a first asset specifically designed for an AI-identified subgroup of patients with autism.